Deutsche Bank began coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report sent to investors on Tuesday morning. The firm issued a buy rating and a $175.00 target price on the pharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. DA Davidson started coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a buy rating and a $200.00 target price on the stock. BTIG Research started coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a buy rating and a $200.00 target price on the stock. BMO Capital Markets reiterated a buy rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Needham & Company LLC reiterated a buy rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. Finally, Vetr lowered Vertex Pharmaceuticals from a strong-buy rating to a buy rating and set a $181.00 target price on the stock. in a research report on Monday, September 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-four have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $173.22.

Shares of Vertex Pharmaceuticals (VRTX) traded down $2.27 during trading hours on Tuesday, hitting $142.53. The stock had a trading volume of 1,411,300 shares, compared to its average volume of 1,788,207. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $167.85. The stock has a market cap of $36,620.33, a price-to-earnings ratio of 241.33, a price-to-earnings-growth ratio of 3.46 and a beta of 1.58. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same quarter last year, the firm posted $0.16 EPS. The business’s revenue was up 39.7% on a year-over-year basis. analysts forecast that Vertex Pharmaceuticals will post 0.76 earnings per share for the current year.

In other news, EVP Michael Parini sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $152.93, for a total transaction of $324,976.25. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jeffrey M. Leiden sold 125,000 shares of Vertex Pharmaceuticals stock in a transaction on Monday, December 11th. The stock was sold at an average price of $141.35, for a total value of $17,668,750.00. Following the transaction, the chief executive officer now owns 237,407 shares in the company, valued at approximately $33,557,479.45. The disclosure for this sale can be found here. Insiders sold a total of 343,519 shares of company stock worth $49,488,660 in the last 90 days. 1.80% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of VRTX. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after acquiring an additional 132 shares during the period. FNY Partners Fund LP raised its holdings in shares of Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after acquiring an additional 900 shares during the period. Smithfield Trust Co. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $135,000. FNY Managed Accounts LLC purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $162,000. Finally, Dupont Capital Management Corp purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth $186,000. Institutional investors and hedge funds own 93.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/15/vertex-pharmaceuticals-vrtx-research-coverage-started-at-deutsche-bank.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related stocks with our FREE daily email newsletter.